Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PGNX's Cash to Debt is ranked higher than
99% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. PGNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PGNX' s Cash to Debt Range Over the Past 10 Years
Min: 65  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.71
PGNX's Equity to Asset is ranked higher than
54% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PGNX: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
PGNX' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.88 Max: 0.98
Current: 0.71
0.31
0.98
Interest Coverage No Debt
PGNX's Interest Coverage is ranked higher than
98% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PGNX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 6
Z-Score: 4.97
M-Score: 16.47
WACC vs ROIC
26.89%
86.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 14.98
PGNX's Operating margin (%) is ranked higher than
83% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. PGNX: 14.98 )
Ranked among companies with meaningful Operating margin (%) only.
PGNX' s Operating margin (%) Range Over the Past 10 Years
Min: -878.82  Med: -71.63 Max: 14.98
Current: 14.98
-878.82
14.98
Net-margin (%) 15.55
PGNX's Net-margin (%) is ranked higher than
86% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. PGNX: 15.55 )
Ranked among companies with meaningful Net-margin (%) only.
PGNX' s Net-margin (%) Range Over the Past 10 Years
Min: -876.82  Med: -64.28 Max: 15.55
Current: 15.55
-876.82
15.55
ROE (%) 12.07
PGNX's ROE (%) is ranked higher than
88% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. PGNX: 12.07 )
Ranked among companies with meaningful ROE (%) only.
PGNX' s ROE (%) Range Over the Past 10 Years
Min: -87.75  Med: -33.65 Max: 16.86
Current: 12.07
-87.75
16.86
ROA (%) 8.18
PGNX's ROA (%) is ranked higher than
89% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. PGNX: 8.18 )
Ranked among companies with meaningful ROA (%) only.
PGNX' s ROA (%) Range Over the Past 10 Years
Min: -79.08  Med: -25.15 Max: 14.53
Current: 8.18
-79.08
14.53
ROC (Joel Greenblatt) (%) 355.28
PGNX's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. PGNX: 355.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PGNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1585.16  Med: -413.77 Max: 355.28
Current: 355.28
-1585.16
355.28
Revenue Growth (3Y)(%) -32.50
PGNX's Revenue Growth (3Y)(%) is ranked lower than
80% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. PGNX: -32.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PGNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.5  Med: -15.8 Max: 72.1
Current: -32.5
-55.5
72.1
EBITDA Growth (3Y)(%) -17.30
PGNX's EBITDA Growth (3Y)(%) is ranked lower than
68% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. PGNX: -17.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PGNX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -46.4  Med: -8.3 Max: 50.5
Current: -17.3
-46.4
50.5
EPS Growth (3Y)(%) -18.10
PGNX's EPS Growth (3Y)(%) is ranked lower than
65% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. PGNX: -18.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PGNX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.5  Med: -6.15 Max: 221.1
Current: -18.1
-73.5
221.1
» PGNX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

PGNX Guru Trades in Q4 2015

Ken Fisher 140,191 sh (+68.40%)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,370,760 sh (-0.89%)
Chuck Royce 2,282,250 sh (-23.39%)
» More
Q1 2016

PGNX Guru Trades in Q1 2016

Murray Stahl 67,200 sh (unchged)
Ken Fisher 140,191 sh (unchged)
Paul Tudor Jones 2,364,488 sh (-0.26%)
Chuck Royce 2,138,350 sh (-6.31%)
» More
Q2 2016

PGNX Guru Trades in Q2 2016

Mario Gabelli 25,000 sh (New)
Ken Fisher 140,361 sh (+0.12%)
Murray Stahl 67,200 sh (unchged)
Paul Tudor Jones 2,342,388 sh (-0.93%)
Chuck Royce 1,913,350 sh (-10.52%)
» More
Q3 2016

PGNX Guru Trades in Q3 2016

Joel Greenblatt 48,873 sh (New)
Murray Stahl 67,200 sh (unchged)
Chuck Royce 1,728,350 sh (-9.67%)
Ken Fisher 107,663 sh (-23.30%)
Mario Gabelli 17,000 sh (-32.00%)
Paul Tudor Jones 287,813 sh (-87.71%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:VTAE, NAS:ACHN, OTCPK:SNBIF, NAS:NK, NAS:ACRS, NAS:CERS, NAS:NTLA, NAS:ITCI, NAS:RGNX, OTCPK:PHMMF, NAS:ATRA, NAS:INO, NAS:LOXO, NAS:EDIT, NAS:OTIC, NAS:BLCM, NAS:OMER, NAS:KERX, NAS:MYOK, OTCPK:GNFTF » details
Traded in other countries:PGP.Germany,
Progenics Pharmaceuticals Inc is engaged in the development of medicines for oncology. The Company develops products for the treatment of prostate cancer, opioid-induced constipation, or OIC, as well as OIC for non-cancer pain.

Progenics Pharmaceuticals Inc was incorporated in Delaware on December 1, 1986. The Company is engaged in the development of medicines for oncology. Its clinical development centers on late-stage oncology assets. Its product candidates are RELISTOR in injection form for the treatment of opioid induced constipation, or OIC. RELISTOR has received a complete response letter on the pending sNDA for the treatment of OIC in patients with non-cancer pain. The Company, along with Salix Pharmaceuticals, develops and commercializes subcutaneous Relistor internationally other than in Japan. The Company's clinical-stage products in oncology are PSMA ADC, 1404, and Azedra. The PSMA ADC is for the treatment of prostate cancer and is in the Phase 2 testing in chemotherapy-experienced patients completed. The Phase 2 testing is completed on 1404, an imaging agent for prostate cancer. Azedra is in Phase 2b registrational trial under Special Protocol Assessment for the treatment of pheochromocytoma and paraganglioma. The Company and its product candidates is subject to regulations by the U.S. FDA as well as authorities in other countries. The Company faces competition from other companies, universities and research institutions in the U.S. and abroad.

Ratios

vs
industry
vs
history
P/E(ttm) 54.03
PGNX's P/E(ttm) is ranked lower than
72% of the 298 Companies
in the Global Biotechnology industry.

( Industry Median: 27.49 vs. PGNX: 54.03 )
Ranked among companies with meaningful P/E(ttm) only.
PGNX' s P/E(ttm) Range Over the Past 10 Years
Min: 12.75  Med: 112.59 Max: 925
Current: 54.03
12.75
925
PE(NRI) 54.03
PGNX's PE(NRI) is ranked lower than
73% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 27.33 vs. PGNX: 54.03 )
Ranked among companies with meaningful PE(NRI) only.
PGNX' s PE(NRI) Range Over the Past 10 Years
Min: 12.75  Med: 112.59 Max: 925
Current: 54.03
12.75
925
Price/Owner Earnings (ttm) 49.93
PGNX's Price/Owner Earnings (ttm) is ranked lower than
64% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. PGNX: 49.93 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PGNX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 22.12  Med: 55.03 Max: 144.53
Current: 49.93
22.12
144.53
P/B 5.42
PGNX's P/B is ranked lower than
67% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: 3.57 vs. PGNX: 5.42 )
Ranked among companies with meaningful P/B only.
PGNX' s P/B Range Over the Past 10 Years
Min: 1.08  Med: 3.54 Max: 8.82
Current: 5.42
1.08
8.82
P/S 8.68
PGNX's P/S is ranked higher than
61% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. PGNX: 8.68 )
Ranked among companies with meaningful P/S only.
PGNX' s P/S Range Over the Past 10 Years
Min: 1.88  Med: 9.15 Max: 177.27
Current: 8.68
1.88
177.27
PFCF 45.98
PGNX's PFCF is ranked lower than
67% of the 156 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. PGNX: 45.98 )
Ranked among companies with meaningful PFCF only.
PGNX' s PFCF Range Over the Past 10 Years
Min: 11.01  Med: 32.59 Max: 278.57
Current: 45.98
11.01
278.57
POCF 36.61
PGNX's POCF is ranked lower than
64% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 20.45 vs. PGNX: 36.61 )
Ranked among companies with meaningful POCF only.
PGNX' s POCF Range Over the Past 10 Years
Min: 10.86  Med: 30.55 Max: 205.26
Current: 36.61
10.86
205.26
EV-to-EBIT 48.35
PGNX's EV-to-EBIT is ranked lower than
80% of the 317 Companies
in the Global Biotechnology industry.

( Industry Median: 20.32 vs. PGNX: 48.35 )
Ranked among companies with meaningful EV-to-EBIT only.
PGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -50.8  Med: -3.9 Max: 301.4
Current: 48.35
-50.8
301.4
EV-to-EBITDA 40.53
PGNX's EV-to-EBITDA is ranked lower than
77% of the 346 Companies
in the Global Biotechnology industry.

( Industry Median: 16.98 vs. PGNX: 40.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
PGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.8  Med: -4.05 Max: 233.2
Current: 40.53
-132.8
233.2
Current Ratio 7.71
PGNX's Current Ratio is ranked higher than
69% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. PGNX: 7.71 )
Ranked among companies with meaningful Current Ratio only.
PGNX' s Current Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.42 Max: 32.92
Current: 7.71
2.67
32.92
Quick Ratio 7.71
PGNX's Quick Ratio is ranked higher than
70% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. PGNX: 7.71 )
Ranked among companies with meaningful Quick Ratio only.
PGNX' s Quick Ratio Range Over the Past 10 Years
Min: 2.67  Med: 11.42 Max: 32.92
Current: 7.71
2.67
32.92
Days Sales Outstanding 20.59
PGNX's Days Sales Outstanding is ranked higher than
81% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. PGNX: 20.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
PGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.36  Med: 32.86 Max: 180.24
Current: 20.59
0.36
180.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.50
PGNX's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. PGNX: -14.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -73.6  Med: -11.6 Max: -2.1
Current: -14.5
-73.6
-2.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.52
PGNX's Price/Net Cash is ranked lower than
69% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: 6.19 vs. PGNX: 11.52 )
Ranked among companies with meaningful Price/Net Cash only.
PGNX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.59  Med: 6.44 Max: 22.41
Current: 11.52
1.59
22.41
Price/Net Current Asset Value 10.05
PGNX's Price/Net Current Asset Value is ranked lower than
70% of the 1006 Companies
in the Global Biotechnology industry.

( Industry Median: 5.65 vs. PGNX: 10.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PGNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.48  Med: 5.85 Max: 18.68
Current: 10.05
1.48
18.68
Price/Tangible Book 9.00
PGNX's Price/Tangible Book is ranked lower than
76% of the 1150 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. PGNX: 9.00 )
Ranked among companies with meaningful Price/Tangible Book only.
PGNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.22  Med: 5.13 Max: 13.49
Current: 9
1.22
13.49
Price/Median PS Value 0.95
PGNX's Price/Median PS Value is ranked higher than
53% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. PGNX: 0.95 )
Ranked among companies with meaningful Price/Median PS Value only.
PGNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 1.33 Max: 14.3
Current: 0.95
0.25
14.3
Price/Graham Number 4.65
PGNX's Price/Graham Number is ranked lower than
74% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. PGNX: 4.65 )
Ranked among companies with meaningful Price/Graham Number only.
PGNX' s Price/Graham Number Range Over the Past 10 Years
Min: 2.02  Med: 4.19 Max: 15.87
Current: 4.65
2.02
15.87
Earnings Yield (Greenblatt) (%) 2.09
PGNX's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. PGNX: 2.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PGNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 2 Max: 10.2
Current: 2.09
0.3
10.2

More Statistics

Revenue (TTM) (Mil) $69.87
EPS (TTM) $ 0.16
Beta3.27
Short Percentage of Float18.32%
52-Week Range $3.61 - 9.23
Shares Outstanding (Mil)70.05

Analyst Estimate

Dec16 Dec18
Revenue (Mil $) 73 123
EPS ($) 0.14 0.55
EPS w/o NRI ($) 0.14 0.55
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Oct 04 2010 

More From Other Websites
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor Nov 30 2016
ETFs with exposure to Progenics Pharmaceuticals, Inc. : November 23, 2016 Nov 23 2016
Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21,... Nov 21 2016
PROGENICS PHARMACEUTICALS INC Financials Nov 16 2016
ETF’s with exposure to Progenics Pharmaceuticals, Inc. : November 11, 2016 Nov 11 2016
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US :... Nov 10 2016
Progenics Pharmaceuticals to Present at Upcoming Investor Conferences Nov 08 2016
Progenics Pharmaceuticals to Present at Upcoming Investor Conferences Nov 08 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 07 2016
Progenics posts 3Q profit Nov 07 2016
Progenics posts 3Q profit Nov 07 2016
Progenics Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today Nov 07 2016
Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results and Business Update Nov 07 2016
Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results and Business Update Nov 07 2016
Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing Nov 07 2016
Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing Nov 07 2016
Portfolio Cuts Couldn’t Stop HealthInvest From Buying Up These Stocks Oct 29 2016
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events Oct 28 2016
Coverage initiated on Progenics Pharm by Aegis Capital Oct 27 2016
Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call for November 7 Oct 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)